Skip to main
NPCE
NPCE logo

NeuroPace (NPCE) Stock Forecast & Price Target

NeuroPace (NPCE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 64%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

NeuroPace Inc. reported a notable improvement in gross margin, with figures rising to 73.6% in 1Q24 from 71.7% in 1Q23, attributed to enhanced manufacturing efficiencies and increased sales of the RNS System. The company experienced robust revenue growth of approximately 41% year-over-year, achieving total revenue of $18.0 million, primarily driven by the heightened adoption of the RNS System despite a slight decline in replacement implant revenue. Looking ahead, NeuroPace anticipates continued strong performance in the second half of the year, supported by enhanced utilization in Level 4 centers and broader community engagement initiatives.

Bears say

NeuroPace Inc. continues to face significant financial challenges, highlighted by a historical record of net losses, which raises concerns about its long-term viability and growth prospects. The company heavily relies on a limited number of suppliers, making it vulnerable to supply chain disruptions and price volatility that could negatively impact its financial condition. Additionally, potential liabilities from data privacy issues pose further risks to the business, further complicating its path to sustainable profitability.

NeuroPace (NPCE) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 64% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroPace (NPCE) Forecast

Analysts have given NeuroPace (NPCE) a Buy based on their latest research and market trends.

According to 11 analysts, NeuroPace (NPCE) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroPace (NPCE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.